"Receptors, Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
Descriptor ID |
D017481
|
MeSH Number(s) |
D12.776.543.750.695.850 D12.776.543.750.720.600.760 D12.776.543.750.750.555.760 D12.776.543.750.750.580.720 D12.776.543.750.750.700.800
|
Concept/Terms |
Receptors, Somatostatin- Receptors, Somatostatin
- Somatostatin Receptors
- SRIH Receptors
- Receptors, Somatotropin Release Inhibiting Hormone
- Receptors, SRIH
- Somatostatin Receptor
- Receptor, Somatostatin
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Somatostatin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Somatostatin [D12.776.543.750.695.850]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Somatostatin [D12.776.543.750.720.600.760]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Somatostatin [D12.776.543.750.750.555.760]
- Receptors, Pancreatic Hormone [D12.776.543.750.750.580]
- Receptors, Somatostatin [D12.776.543.750.750.580.720]
- Receptors, Pituitary Hormone-Regulating Hormone [D12.776.543.750.750.700]
- Receptors, Somatostatin [D12.776.543.750.750.700.800]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Somatostatin".
This graph shows the total number of publications written about "Receptors, Somatostatin" by people in this website by year, and whether "Receptors, Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2017 | 3 | 2 | 5 |
2018 | 3 | 2 | 5 |
2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Somatostatin" by people in Profiles.
-
Role of Peptides in Diagnostics. Int J Mol Sci. 2021 Aug 17; 22(16).
-
Somatostatin receptor imaging in active cardiac sarcoidosis: Would less be enough? J Nucl Cardiol. 2021 Jun; 28(3):1100-1104.
-
Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review. Crit Rev Oncol Hematol. 2019 Jun; 138:29-37.
-
Strain-specific metastatic phenotypes in pheochromocytoma allograft mice Endocr Relat Cancer. 2018 10 05; 25(12):993-1004.
-
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. 2018 Jun; 21(3):302-308.
-
Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol. 2018 09; 79:144-150.
-
Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol. 2018 06; 61:36-44.
-
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer. 2018 06; 25(6):R351-R364.
-
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017 Nov; 18(16):1679-1689.
-
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017 08; 44(9):1588-1601.